alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2019302EN.01000101.xml

| 6.9.2019 | EN | Official Journal of the European Union | C 302/1 |
| --- | --- | --- | --- |

6.9.2019

EN

Official Journal of the European Union

C 302/1

---

COUNCIL DECISION

of 3 September 2019

adopting the Council’s position on the draft general budget of the European Union for the financial year 2020

(2019/C 302/01)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 314(3) thereof, in conjunction with the Treaty establishing the European Atomic Energy Community and in particular Article 106a thereof,

Whereas:

| (1) | On 5 June 2019, the Commission submitted a proposal containing the draft general budget of the European Union for the financial year 2020 (1). |
| --- | --- |

(1)

On 5 June 2019, the Commission submitted a proposal containing the draft general budget of the European Union for the financial year 2020 (1).

| (2) | The Council examined the Commission proposal with a view to defining a position consistent, on the revenue side, with Council Decision 2014/335/EU, Euratom of 26 May 2014 on the system of own resources of the European Union (2), and, on the expenditure side, with Council Regulation (EU, Euratom) No 1311/2013 of 2 December 2013 laying down the multiannual financial framework for the years 2014-2020 (3), |
| --- | --- |

(2)

The Council examined the Commission proposal with a view to defining a position consistent, on the revenue side, with Council Decision 2014/335/EU, Euratom of 26 May 2014 on the system of own resources of the European Union (2), and, on the expenditure side, with Council Regulation (EU, Euratom) No 1311/2013 of 2 December 2013 laying down the multiannual financial framework for the years 2014-2020 (3),

HAS DECIDED AS FOLLOWS:

Sole Article

The Council’s position on the draft general budget of the European Union for the financial year 2020 was adopted by the Council on 3 September 2019.

The full text can be accessed for consultation or downloading on the Council’s website: http://www.consilium.europa.eu/

Done at Brussels, 3 September 2019.

For the Council

The President

T. TUPPURAINEN

---

(1)  COM(2019) 400 final.

1

(2)  OJ L 168, 7.6.2014, p. 105.

2

(3)  OJ L 347, 20.12.2013, p. 884.

3

---
Investment Properties Associates Announces the
         Sale of 245 Fifth Avenue and 261 Fifth Avenue, New York, N.Y.

New York,  New York  April 19,  2000...Investment  Properties  Associates  (IPA)
announced  today that it has signed a contract to sell 245 Fifth  Avenue and 261
Fifth  Avenue,  New  York,  N.Y.  for  $135,000,000.  The  purchaser  is a  fund
controlled by Koll Bren Schreiber  Realty  Advisors Inc. The closing is expected
to occur within approximately 35 days.

The  determination  of the  size of the  special  distribution  from  the  sales
proceeds will be made  subsequently,  after the  completion  of the  transaction
accounting and establishment of appropriate  reserves.  In accordance with IPA's
partnership  agreement,  one-half of the net proceeds will be distributed to the
general  and  special  limited  partners  and  one-half  to the  holders  of its
participations of limited partnership interests.

Upon the consummation of this proposed  transaction,  IPA's remaining properties
consist of two undeveloped  parcels in Houston,  Texas and one vacant commercial
office building in Newark, New Jersey.

The sale of 245 Fifth Avenue and 261 Fifth Avenue,  New York,  N.Y. was approved
by all of the general  partners  of IPA  including  ScogBell  AG,  Inc.,  Irving
Schneider  and  Minlyn,  Inc.  Helmsley-Spear,  Inc.  represented  IPA  in  this
transaction.

IPA was created in 1969 by Harry Helmsley and Irving Schneider. Irving Schneider
said that IPA was  continuing  to explore  the  possible  sale of its  remaining
properties,  but  there  could  be no  assurances  that any  such  sale  will be
concluded.

Contact:      Irving Schneider - (212) 880-0151
              General Partner, Investment Properties Associates
              Co-Chairman & Chief Operating Officer, Helmsley-Spear, Inc., Agent

              Robert Hecht - (212) 880-0276
              Chief Financial Officer, Investment Properties Associates
              Vice President of Finance, Helmsley-Spear, Inc., Agent
#### CECILE SCHEFFER v. PEDER M. HAGE AND OTHERS.1

October 26, 1923.

No. 23,768.

Appeal dismissed because of absence of settled case and bill of exceptions.

Appeal dismissed for failure of appellant to settle a case or bill of exceptions, the attempted appeal being from an order denying a motion for a new trial made upon the minutes of the court under section 7829, G. S. 1913.

From an order of the municipal court of St. Paul, Rounds, J., denying his motion for a new trial upon minutes of the court, Peder M. Hage appealed.

Appeal dismissed.

*Peder M. Hage,*pro se.

*McGrath & Morse,*for respondents.

1

 Reported in 195 N. W. 453.

*15Pee Gubiam.

This is an appeal from an order of the municipal court of the city of St. Paul, denying a motion for new trial, made upon the minutes of the court, upon the sole ground that the statutory period for the making of such a motion had expired. Leave was granted to appellant to move for a new trial “upon the record herein within the time allowed in and by the stipulation entered into between the counsel for the parties hereto.” No advantage was taken of that provision of the order denying his motion made on the minutes, but, without any further effort at a review of the proceedings in the trial court, and without a settled case or bill of exceptions, defendant Hage has attempted this appeal. The statute concerning motions for new trial “on the minutes” (section 7829, G. S. 1913), provides that on appeal from an order denying such a motion, “a case or bill of exceptions shall be proposed by the appellant, and be settled and returned with the record to the supreme court.” Of course that statute is mandatory and because of appellant’s failure to comply with it his appeal must be dismissed.

It is so ordered.
EXHIBIT 11 - Statement Re:  Computation of Earnings Per Share

<TABLE>
<CAPTION>

------------------------------------------------------------------------------
                                         Three Months Ended   Six Months Ended
                                               June 30,           June 30,
(In thousands)                             1997     1996(1)    1997     1996(1)
------------------------------------------------------------------------------
<S>                                      <C>       <C>       <C>       <C>    
Primary
     Average shares outstanding ......    16,912    17,762    17,036    17,886
     Common stock equivalents:
         Net effect of the assumed
         exercise of stock options and
         stock warrants based on
         average market price ........       311       446       346       448
                                         -------   -------   -------   -------

Primary average shares ...............    17,223    18,208    17,382    18,334
                                         =======   =======   =======   =======

Net income applicable to common
     shares ..........................   $ 4,713   $ 4,146   $ 8,669   $ 6,773

Primary net income per share .........   $   .27   $   .23   $   .50   $   .37

<CAPTION>
------------------------------------------------------------------------------
<S>                                      <C>       <C>       <C>       <C>    
Fully diluted
     Average shares outstanding ......    16,912    17,762    17,036    17,886
     Common stock equivalents:
         Net effect of the assumed
         exercise of stock options and
         stock warrants based on end
         of period market price ......       346       446       364       450
                                         -------   -------   -------   -------

Fully diluted average shares .........    17,258    18,208    17,400    18,336
                                         =======   =======   =======   =======

Net income applicable to common
     shares ..........................   $ 4,713   $ 4,146   $ 8,669   $ 6,773

Fully diluted net income per share ...   $   .27   $   .23   $   .50   $   .37

<FN>
(1)   Share figures for 1996 have been restated for the 10% stock dividend 
      issued in December 1996.
</TABLE>
§ 203.50 Requirements for wholesale distribution of prescription drugs. ( a ) *Identifying statement for sales by unauthorized distributors.* Before the completion of any wholesale distribution by a wholesale distributor of a prescription drug for which the seller is not an authorized distributor of record to another wholesale distributor or retail pharmacy, the seller shall provide to the purchaser a statement identifying each prior sale, purchase, or trade of such drug. This identifying statement shall include: ( 1 ) The proprietary and established name of the drug;
( 2 ) Dosage;
( 3 ) Container size;
( 4 ) Number of containers;
( 5 ) The drug's lot or control number(s);
( 6 ) The business name and address of all parties to each prior transaction involving the drug, starting with the manufacturer; and
( 7 ) The date of each previous transaction.
( b ) The drug origin statement is subject to the record retention requirements of § 203.60 and must be retained by all wholesale distributors involved in the distribution of the drug product, whether authorized or unauthorized, for 3 years.
( c ) *Identifying statement not required when additional manufacturing processes are completed.* A manufacturer that subjects a drug to any additional manufacturing processes to produce a different drug is not required to provide to a purchaser a statement identifying the previous sales of the component drug or drugs.
( d ) *List of authorized distributors of record.* Each manufacturer shall maintain at the corporate offices a current written list of all authorized distributors of record. ( 1 ) Each manufacturer's list of authorized distributors of record shall specify whether each distributor listed thereon is authorized to distribute the manufacturer's full product line or only particular, specified products.
( 2 ) Each manufacturer shall update its list of authorized distributors of record on a continuing basis.
( 3 ) Each manufacturer shall make its list of authorized distributors of record available on request to the public for inspection or copying. A manufacturer may impose reasonable copying charges for such requests from members of the public.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   12-MOS                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997             DEC-31-1998
<PERIOD-END>                               DEC-31-1997             DEC-31-1998
<CASH>                                           2,657                   4,553
<SECURITIES>                                         0                       0
<RECEIVABLES>                                   24,015                  33,867
<ALLOWANCES>                                       551                     621
<INVENTORY>                                     26,200                  35,548
<CURRENT-ASSETS>                                63,106                  86,660
<PP&E>                                         104,230                 118,215
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                                 181,291                 225,815
<CURRENT-LIABILITIES>                           21,418                  41,058
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                           707                     707
<OTHER-SE>                                     136,254                 161,269
<TOTAL-LIABILITY-AND-EQUITY>                   181,291                 225,815
<SALES>                                        193,984                 231,934
<TOTAL-REVENUES>                               193,984                 231,934
<CGS>                                           75,393                  86,134
<TOTAL-COSTS>                                   75,393                  86,134
<OTHER-EXPENSES>                                85,585                 104,495
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                               1,181                   2,109
<INCOME-PRETAX>                                 31,825                  39,196
<INCOME-TAX>                                    12,221                  15,051
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                    19,604                  24,145
<EPS-PRIMARY>                                     0.28                    0.34
<EPS-DILUTED>                                     0.28                    0.34
        

</TABLE>
[No. 39884-9-I.

Division One.

January 26, 1998.]

#### The State of Washington, *Respondent,*v. Victor Leroy Perkins, *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-1-04442-0, Joan DuBuque, J., entered December 16, 1996. *Affirmed*by unpublished per curiam opinion.
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Wayside Technology Group, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Simon F. Nynens, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

| (1)    | The Report fully complies with the requirements of   Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                                  |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                     |
| (2)    | The information contained in the Report fairly presents,   in all material respects, the financial condition and results of operations   of the Company. |

| /s/  Simon F.   Nynens           |   |
|---------------------------------------|--------|
|                                       |   |
| Simon F. Nynens                       |   |
| President and Chief Executive Officer |   |
| March 12, 2007                        |   |

*A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by Company and furnished to the Securities and Exchange Commission or its staff upon request.*
§ 510.105 Labeling of drugs for use in milk-producing animals. ( a ) Part 526 of this chapter provides for new animal drugs intended for intramammary use in animals and includes conditions of use intended to prevent the contamination of milk from the use of such drugs.
( b ) Preparations containing antibiotics and other potent drugs labeled with directions for use in milk-producing animals will be misbranded under section 502(f)(2) of the act unless their labeling bears appropriate warnings and directions for use to avoid adulteration of milk under section 402(a)(2)(c)(ii) of the act.
( c ) It is the position of the Food and Drug Administration that the labeling for such preparations should bear a clear warning that either: ( 1 ) The article should not be administered to animals producing milk, since to do so would result in contamination of the milk; or
( 2 ) The label should bear the following statement: “Warning: Milk that has been taken from animals during treatment and for __ hours after the latest treatment must not be used for food”, the blank being filled in with the figure that the manufacturer has determined by appropriate investigation is needed to insure that the milk will not carry violative residues resulting from use of the preparation. If the use of the preparation as recommended does not result in contamination of the milk, neither of the above warning statements is required.
[40 FR 13807, Mar. 27, 1975, as amended at 63 FR 32980, June 17, 1998; 64 FR 51241, Sept. 22, 1999]
CERTIFICATION PURSUANT TO SECTION
                          302 OF THE SARBANES OXLEY ACT


I, Roger Juhnke, certify that:

1. I have  reviewed  this  quarterly  report on Form 10-QSB of Tonga Capital
Corp.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

<PAGE>

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The  registrant's  other  certifying  officers  and I have  indicated in this
quarterly report whether there were significant  changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent  evaluation,  including any corrective  actions with
regard to significant deficiencies and material weaknesses.

Date: November __, 2003


/s/ Roger Juhnke
- -----------------------
 Roger Juhnke, CEO and CFO
UNITED STATES DEPARTMENT OF TRANSPORTATION 

OFFICE OF HEARINGS 

WASHINGTON, D.C. 

IN THE MATTER OF 

MARTINAIRE AVIATION, LLC 

FAA DOCKET NO. [TO BE ASSIGNED] 

FDMS NO. FAA-2013-0040 

FAA Case No. 2011SW700189 

(Civil Penalty Action) 

Judge Richard C. Goodwin 

NOTICE OF APPEAL 

RECEIVED 

APR 1 7 2015 

HEARING DOCKET 

Comes now the Administrator, acting through his Regional 

Counsel, and files this Notice of Appeal of the Initial Decision 

served April 10, 2015, in the above numbered and entitled matter 

pursuant to 14 C.F.R. § 13.233(a) of the Rules of Practice For 

FAA Civil Penalty Actions. 

ERIC E. ANDERSON 

"~-Regional --l5 

/ Southwest 

James Archier, Attorney 

General Litigation & 

Rulemaking Branch 

Federal Aviation Administration 

Fort Worth, Texas 76137 

(817) 222-5074, FAX: (817) 222-5092 

e-mail: james.archier@faa.gov 

Dated: April 16, 2015 
CERTIFICATE OF SERVICE 

I hereby certify that I have this date mailed via Federal 

Express an original and one copy of the Administrator's Notice 

of Appeal addressed to the following: 

Federal Aviation Administration 

600 Independence Avenue, SW., 

Wilbur Wright Building-Suite 2W1000 

Washington, DC 20591 

Attention: Hearing Docket Clerk, AGC-430 

I hereby certify that I have this date mailed via Federal 

Express one copy of the Administrator's Notice of Appeal 

addressed to the following: 

By: 

Jam s 

Michael L. Dworkin, Respondent's Counsel 

Michael L. Dworkin and Associates Law Offices 

465 California Street, Suite 210 

San Francisco, California 94104-1808 

TEL: (415) 421-2500 

FAX: (415) 2560 

' 

Dated: April 16, 2015 

F eral Aviation Administration 

~ /office of the Regional Counsel 

I

' // Southwest Region 

/, 2601 Meacham Blvd., 

L-/e Fort Worth, Texas 76137 

(817) 222-5074 

2
Exhibit
32.2








CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002








In
connection with the Annual Report of Astea International Inc. (the “Company”) on
Form 10-K for the period ending December 31, 2009 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Rick Etskovitz,
Chief Financial Officer and Principal Financial and Chief Accounting Officer of
the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906
of the Sarbanes-Oxley Act of 2002, that:





(1)
            The
      Report fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.




















/s/Rick EtskovitzRick
      EtskovitzChief
      Financial Officer(Principal
      Financial and Accounting Officer)March
      25, 2010












82
Argued and submitted October 29,

reversed and remanded November 24, 1999

#### STATE OF OREGON, *Respondent, v.*MERRILL MARK STECKLER, *Appellant.*

(980140295; CA A102031)

991 P2d 577

Monica L. Finch, Deputy Public Defender, argued the cause for appellant. With her on the brief was David E. Groom, Public Defender.

Jonathan H. Fussner, Assistant Attorney General, argued the cause for respondent. With him on the brief were Hardy Myers, Attorney General, and Michael D. Reynolds, Solicitor General.

Before De Muniz, Presiding Judge, and Haselton and Wollheim, Judges.

PER CURIAM

Reversed and remanded. *State v. Moore,*159 Or App 144, 978 P2d 395, *rev allowed*329 Or 438 (1999).
### D ISTRICT 

### C OURT 

### O F 

### APPEAL 

### O F 

### F LORIDA 

### S ECOND 

### D ISTRICT MICHAEL JOSEPH NACHREINER,

Appellant, v. STATE OF FLORIDA, Appellee. No. 2D22-2195 November 15, 2023 Appeal from the Circuit Court for Pasco County; Mary M. Handsel, Judge. Howard L. Dimmig, II, Public Defender, and Clark E. Green, Assistant Public Defender, Bartow, for Appellant.Ashley Moody, Attorney General, Tallahassee, and Natalia ReynaPimiento, Assistant Attorney General, Tampa, for Appellee. PER CURIAM. Affirmed. SILBERMAN, LaROSE, and ATKINSON, JJ., Concur. Opinion subject to revision prior to official publication.